Information Provided By: 
Fly News Breaks for September 10, 2019
IONS
Sep 10, 2019 | 08:13 EDT
As previously reported, Bernstein analyst Vincent Chen upgraded Ionis Pharmaceuticals to Outperform from Market Perform and raised his price target on the shares to $80 from $70. The analyst cites lower Spinraza expectations, with further downside likely limited, and value-creating catalysts for the Huntington's program that seem not so far away. Chen recommends owning the stock going into the upcoming RG6042 OLE readout.
News For IONS From the Last 2 Days
There are no results for your query IONS
